
AYR Wellness reports first Ohio transfer to noteholder buyer
State approvals cleared the Oct. 1 transfer of certain Ohio operations; AYR disclosed no cash proceeds or debt relief figure.

TVA's Clinch River permit took effect Sept. 28; GE Vernova's Sept. 29 release states no equipment price or delivery date.

State approvals cleared the Oct. 1 transfer of certain Ohio operations; AYR disclosed no cash proceeds or debt relief figure.

One petition is active and the other pending review; both would let Florida medical operators sell to adults if voters approve.
TransAlta sought US$19.9M for the first 90 days of a federal emergency order; FERC rejected the proposed allocation of those costs.
The TSX Venture company has issued US$10.5 million of secured convertible notes and will seek shareholder approval for preferred shares on Oct. 14.

We Energies says Oracle would take on part of its required nuclear power purchase; Oracle says the subscription needs Wisconsin commission approval.

SITC presentations will follow a three-year EVX-01 clinical update on Oct. 24; the 75% response rate was first reported in 2025.

Surrozen expects to dose DUET's first patient in Q4; clearance also meets a condition for a US$95.1M financing close around Oct. 20.

The first-line application is expected to be completed by year end; a separate monotherapy NDA has a Feb. 27, 2027 FDA target.
Argentina's incentive regime offers 30 years of stability as Glencore advances Alumbrera's first-production target to the second half of 2027.
The ARTG's Sept. 15 entry names Jupiter Research as manufacturer; Curaleaf also reports a Sept. 17 New Zealand WAND notification.
Facility A begins at 7.25 per cent and Facility B stays at 9.95 per cent under a Sept. 28 agreement backed by subsidiary assets.
Shareholders approved the Armada combination Sept. 30, while Evernorth expects roughly US$300M of gross cash before expenses.
Colorado completed its review on Sept. 29; permit issuance requires verified warranties, and DOE mine-plan approval remains pending.
The Erwin, Tennessee, unit will make reactor fuel for the naval propulsion program, with work scheduled for completion in August 2027.
The uncontrolled Canadian trial enrolled 11 patients; seven were evaluable for pain, and validated data analysis remains underway.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The Oct. 1 filing attributes the joint termination to delayed closing and gives no figure for any termination payment.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
AstraZeneca or Daiichi Sankyo will sponsor the planned breast cancer study, with all three companies sharing trial costs and retaining drug rights.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
About 40 gas units are set for staged deployment from late 2026, with revenue expected to begin in the first quarter of 2027.
Gross margin reached about 48 per cent in the June half, while WISeQey shares are due to trade as WQEY on Oct. 5 after an ADS conversion.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
Marimaca's Oct. 1 update names no supplier, contracted volume or energization date for its preliminary five-year power framework.

Commerce's Bureau of Industry and Security authorised sales under specified terms; the company did not name an export buyer or shipment date.

The proposed transfer covers seven reactors and related liabilities, but the Sept. 30 notice gives no price or signing date.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
Lifted Made closed the Kenosha building sale Sept. 29 and used US$841,110 to repay all its outstanding bank debt.

A Sept. 29 stay in DEA hearing docket 26-96 sets Oct. 13 for a response to a motion seeking to add the GAO report to the record.

Holders have until Oct. 23 to vote on one new share for five to 15 existing shares, nomination rules and incentive-plan entitlements.

Battle Green can require a share-funded note purchase, while Vireo can trigger one at a lower share price; the maturity route uses a future trading average.